Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis

M. Lebwohl; E. Ast; J. P. Callen; S. I. Cullen; S. R. Hong; C. L. Kulp-Shorten; N. J. Lowe; T. J. Phillips; T. Rosen; D. I. Wolf; J. M. Quell; J. Sefton; J. C. Lue; J. R. Gibson; R. A.S. Chandraratna

doi:10.1016/S0190-9622(98)70594-8

Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis

M. Lebwohl, E. Ast, J. P. Callen, S. I. Cullen, S. R. Hong, C. L. Kulp-Shorten, N. J. Lowe, T. J. Phillips, T. Rosen, D. I. Wolf, J. M. Quell, J. Sefton, J. C. Lue, J. R. Gibson, R. A.S. Chandraratna

Research output: Contribution to journal › Article › peer-review

91 Scopus citations

Abstract

Background: A new class of topical receptor-selective acetylenic retinoids, the first of which is tazarotene, has been developed. Objective: Our purpose was to compare the safety, efficacy, and duration of therapeutic effect of 12 weeks of once-daily tazarotene 0.1% and 0.05% gel with that of twice-daily fluocinonide 0.05% cream in the treatment of patients with plaque psoriasis. Methods: Three hundred forty-eight patients with plaque psoriasis were enrolled and 275 patients completed a multicenter, investigator-masked, randomized, parallel-group clinical trial. Results: Both tazarotene gels were as effective as fluocinonide in reducing plaque elevation after 1 week of treatment, and tazarotene 0.1% gel was similar to fluocinonide in reducing scaling of trunk/limb lesions at all study weeks except week 4. Tazarotene 0.1% gel was similar to fluocinonide in reducing scaling of knee/elbow lesions at weeks 8 and 12. Fluocinonide had a significantly greater effect on erythema than tazarotene at weeks 2 through 8. However, treatments were not significantly different at week 12, and tazarotene demonstrated significantly better maintenance of therapeutic effect after cessation of therapy. Conclusion: Tazarotene 0.1% and 0.05% gels were safe and effective in the treatment of mild-to-moderate plaque psoriasis.

Original language	English
Pages (from-to)	705-711
Number of pages	7
Journal	Journal of the American Academy of Dermatology
Volume	38
Issue number	5 I
DOIs	https://doi.org/10.1016/S0190-9622(98)70594-8
State	Published - 1998

Access to Document

10.1016/S0190-9622(98)70594-8

Cite this

Lebwohl, M., Ast, E., Callen, J. P., Cullen, S. I., Hong, S. R., Kulp-Shorten, C. L., Lowe, N. J., Phillips, T. J., Rosen, T., Wolf, D. I., Quell, J. M., Sefton, J., Lue, J. C., Gibson, J. R., & Chandraratna, R. A. S. (1998). Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. Journal of the American Academy of Dermatology, 38(5 I), 705-711. https://doi.org/10.1016/S0190-9622(98)70594-8

@article{5c3a0f2e07c748abbbb920062308e605,

title = "Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis",

abstract = "Background: A new class of topical receptor-selective acetylenic retinoids, the first of which is tazarotene, has been developed. Objective: Our purpose was to compare the safety, efficacy, and duration of therapeutic effect of 12 weeks of once-daily tazarotene 0.1% and 0.05% gel with that of twice-daily fluocinonide 0.05% cream in the treatment of patients with plaque psoriasis. Methods: Three hundred forty-eight patients with plaque psoriasis were enrolled and 275 patients completed a multicenter, investigator-masked, randomized, parallel-group clinical trial. Results: Both tazarotene gels were as effective as fluocinonide in reducing plaque elevation after 1 week of treatment, and tazarotene 0.1% gel was similar to fluocinonide in reducing scaling of trunk/limb lesions at all study weeks except week 4. Tazarotene 0.1% gel was similar to fluocinonide in reducing scaling of knee/elbow lesions at weeks 8 and 12. Fluocinonide had a significantly greater effect on erythema than tazarotene at weeks 2 through 8. However, treatments were not significantly different at week 12, and tazarotene demonstrated significantly better maintenance of therapeutic effect after cessation of therapy. Conclusion: Tazarotene 0.1% and 0.05% gels were safe and effective in the treatment of mild-to-moderate plaque psoriasis.",

author = "M. Lebwohl and E. Ast and Callen, {J. P.} and Cullen, {S. I.} and Hong, {S. R.} and Kulp-Shorten, {C. L.} and Lowe, {N. J.} and Phillips, {T. J.} and T. Rosen and Wolf, {D. I.} and Quell, {J. M.} and J. Sefton and Lue, {J. C.} and Gibson, {J. R.} and Chandraratna, {R. A.S.}",

year = "1998",

doi = "10.1016/S0190-9622(98)70594-8",

language = "English",

volume = "38",

pages = "705--711",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Elsevier Inc.",

number = "5 I",

}

Lebwohl, M , Ast, E, Callen, JP, Cullen, SI, Hong, SR, Kulp-Shorten, CL, Lowe, NJ, Phillips, TJ, Rosen, T, Wolf, DI, Quell, JM, Sefton, J, Lue, JC, Gibson, JR & Chandraratna, RAS 1998, 'Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis', Journal of the American Academy of Dermatology, vol. 38, no. 5 I, pp. 705-711. https://doi.org/10.1016/S0190-9622(98)70594-8

TY - JOUR

T1 - Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis

AU - Lebwohl, M.

AU - Ast, E.

AU - Callen, J. P.

AU - Cullen, S. I.

AU - Hong, S. R.

AU - Kulp-Shorten, C. L.

AU - Lowe, N. J.

AU - Phillips, T. J.

AU - Rosen, T.

AU - Wolf, D. I.

AU - Quell, J. M.

AU - Sefton, J.

AU - Lue, J. C.

AU - Gibson, J. R.

AU - Chandraratna, R. A.S.

PY - 1998

Y1 - 1998

N2 - Background: A new class of topical receptor-selective acetylenic retinoids, the first of which is tazarotene, has been developed. Objective: Our purpose was to compare the safety, efficacy, and duration of therapeutic effect of 12 weeks of once-daily tazarotene 0.1% and 0.05% gel with that of twice-daily fluocinonide 0.05% cream in the treatment of patients with plaque psoriasis. Methods: Three hundred forty-eight patients with plaque psoriasis were enrolled and 275 patients completed a multicenter, investigator-masked, randomized, parallel-group clinical trial. Results: Both tazarotene gels were as effective as fluocinonide in reducing plaque elevation after 1 week of treatment, and tazarotene 0.1% gel was similar to fluocinonide in reducing scaling of trunk/limb lesions at all study weeks except week 4. Tazarotene 0.1% gel was similar to fluocinonide in reducing scaling of knee/elbow lesions at weeks 8 and 12. Fluocinonide had a significantly greater effect on erythema than tazarotene at weeks 2 through 8. However, treatments were not significantly different at week 12, and tazarotene demonstrated significantly better maintenance of therapeutic effect after cessation of therapy. Conclusion: Tazarotene 0.1% and 0.05% gels were safe and effective in the treatment of mild-to-moderate plaque psoriasis.

AB - Background: A new class of topical receptor-selective acetylenic retinoids, the first of which is tazarotene, has been developed. Objective: Our purpose was to compare the safety, efficacy, and duration of therapeutic effect of 12 weeks of once-daily tazarotene 0.1% and 0.05% gel with that of twice-daily fluocinonide 0.05% cream in the treatment of patients with plaque psoriasis. Methods: Three hundred forty-eight patients with plaque psoriasis were enrolled and 275 patients completed a multicenter, investigator-masked, randomized, parallel-group clinical trial. Results: Both tazarotene gels were as effective as fluocinonide in reducing plaque elevation after 1 week of treatment, and tazarotene 0.1% gel was similar to fluocinonide in reducing scaling of trunk/limb lesions at all study weeks except week 4. Tazarotene 0.1% gel was similar to fluocinonide in reducing scaling of knee/elbow lesions at weeks 8 and 12. Fluocinonide had a significantly greater effect on erythema than tazarotene at weeks 2 through 8. However, treatments were not significantly different at week 12, and tazarotene demonstrated significantly better maintenance of therapeutic effect after cessation of therapy. Conclusion: Tazarotene 0.1% and 0.05% gels were safe and effective in the treatment of mild-to-moderate plaque psoriasis.

UR - http://www.scopus.com/inward/record.url?scp=0031901416&partnerID=8YFLogxK

U2 - 10.1016/S0190-9622(98)70594-8

DO - 10.1016/S0190-9622(98)70594-8

M3 - Article

C2 - 9591815

AN - SCOPUS:0031901416

SN - 0190-9622

VL - 38

SP - 705

EP - 711

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 5 I

ER -

Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis

Abstract

Access to Document

Fingerprint

Cite this